Loading company
Sintx Technologies, Inc.
SINT · Nasdaq · ·
$2.04+2.3%Sep 29 close
- 1M
- +36.0%
- 6M
- -10.9%
- 1Y
- -50.1%
- 5Y
- -100.0%
SINT · Nasdaq · ·
$2.04+2.3%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $452K | $151K | +199.34% |
| Profit | -$2.7M | -$2.3M | -16.74% |
| Profit per share | -$0.75 | -$0.91 | +17.58% |
| Free Cash Flow | -$2.9M | -$2.4M | -18.35% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Sintx Technologies, Inc. has no earnings call transcript available.
“Our strategy has always extended well beyond the introduction of a single medical device,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC ® Foot & Ankle Osteotomy Wedge System for reconstructive surgery. NIH Funding Acknowledgment: Research described in this press release relating to the Company’s 3D-printed silicon nitride porous PEEK composite spinal cage program is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R44AR083836. The content is solely the responsibility of SINTX Technologies, Inc. and does not necessarily represent the official views of the National Institutes of Health.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Sintx Technologies, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.